🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 071773105
- Market Cap
- Micro Cap · $56 Million
- Previous Symbol
- BAXS (changed 11/26/2014)
- Previous Name
- TranS1, Inc.
Business: Baxano Surgical, Inc. is a medical device company focused on designing, developing, and marketing products to treat degenerative conditions of the spine affecting the lumbar region. Baxano Surgical currently markets the AxiaLIF family of products for single and two level lumbar fusion, the VEO lateral access and interbody fusion system, and the iO-Flex system, a proprietary minimally invasive set of flexible instruments allowing surgeons to target lumbar spinal stenosis during spinal decompression procedures in all three regions of the spine: central canal, lateral recess, and neural foramen.
Notes: Nov. 13, 2014 -- Baxano Surgical, Inc. (Nasdaq: BAXS) today announced that the Company has filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. The bankruptcy filing was effected in order to facilitate a going concern sale of the Baxano Surgical minimally invasive products. The Company's stock will beging trading on the Other OTC under symbol BAXSQ around 11/26/2014.________________May 31, 2013 -- TranS1 Inc. (Nasdaq:TSON), a medical device company today announced that it has completed its acquisition of Baxano, Inc., a privately-held medical device company. Effective May 31, 2013, following the closing of the Merger, TranS1 merged the wholly-owned subsidiary created by the Merger with and into the Company and changed the name of the Company to Baxano Surgical, Inc. The Company's common stock is expected to begin trading under the new trading symbol BAXS" on June 3, 2013. Under the terms of the merger agreement, RacerX Acquisition Corp., a wholly-owned subsidiary of TranS1 Inc.merged with and into Baxano. Upon the closing of the Merger, and in accordance with the terms of the Merger Agreement, the Company issued an aggregate of approximately 10.3 million shares of the Company's common stock as merger consideration (valued at approximately $20.1 million based on the May 30, 2013 closing price).
Company Contact
- CEO
- Ken Reali
- CFO
- Tim Shannon
- Headquarters
- 110 Horizon Drive, Suite 230, Raleigh, NC 27615
- Phone
- 919-800-0020
- Investor Relations
- Mark Klausner, Westwicke Partners · 443-213-0501 · baxanosurgical@westwicke.com